Comparative Pharmacology
Head-to-head clinical analysis: DILT CD versus PROCARDIA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DILT CD versus PROCARDIA.
DILT-CD vs PROCARDIA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Diltiazem inhibits calcium ion influx during depolarization of cardiac and vascular smooth muscle cells, thereby reducing intracellular calcium levels. It decreases sinoatrial and atrioventricular nodal conduction and dilates coronary and peripheral arteries.
Dihydropyridine calcium channel blocker that inhibits the influx of calcium ions through L-type calcium channels in vascular smooth muscle and cardiac muscle, leading to vasodilation and reduced myocardial contractility.
180-360 mg PO once daily (extended-release); 300-540 mg PO once daily for hypertension; 120-480 mg PO once daily for angina; IV: 0.25 mg/kg bolus over 2 min, then 5-15 mg/hr continuous infusion.
Initial dose: 10 mg orally 3 times daily; maintenance: 10-30 mg 3-4 times daily; maximum 180 mg/day. Extended-release (XL): 30-60 mg once daily; titrate up to 120 mg/day.
None Documented
None Documented
Terminal elimination half-life 7-10 hours; clinically relevant in hepatic impairment (prolonged to 14-20 hours) and in elderly
2-5 hours in healthy adults; up to 6-10 hours in cirrhotic patients or elderly; clinical context: requires extended-release formulations for once-daily dosing.
Renal 2-4% unchanged; extensive hepatic metabolism; 60-70% fecal, 30-40% renal as metabolites
Renal (70-80% as metabolites, <1% unchanged); fecal (15-20% via bile); 0% unchanged in urine.
Category C
Category C
Calcium Channel Blocker
Calcium Channel Blocker